Pfizer Inc. Awards “Golden Tickets” to Neutrolis and Mediar Therapeutics
27 Setembro 2019 - 10:00AM
Business Wire
Winners of the Pfizer Golden Ticket Program
announced last night during a panel discussion and networking event
at Pfizer’s Cambridge, MA R&D site
Pfizer Inc. and LabCentral announced that Pfizer has selected
Neutrolis and Mediar Therapeutics are the winners of this year’s
Pfizer Golden Ticket Program. LabCentral is a first-of-its-kind
shared laboratory space designed as a launchpad for high-potential
life-sciences and biotech startups located in the heart of
Cambridge, MA and proximate to Pfizer’s Kendall Square site. Each
Golden Ticket will provide these startups with waitlist priority
and a voucher for one year of prepaid rent for a reserved bench
space for one scientist, including certain benefits of shared
infrastructure and services.
“Neutrolis and Mediar Therapeutics are both pursuing innovative
science and employing creative approaches to help address complex
and unmet medical needs,” said Morris Birnbaum, MD, PhD, Senior
Vice President and Chief Scientific Officer (CSO), Internal
Medicine Research Unit, Pfizer, Inc. “We are proud to sponsor a
Golden Ticket program and to support local entrepreneurial
innovation that we hope will help catalyze groundbreaking
science.”
The winners were announced last night during an event at
Pfizer’s Kendall Square site that featured a panel discussion on
“approaching collaboration from a ‘developability’ mindset” and
brief presentations from Neutrolis and Mediar Therapeutics. The
event convened Pfizer colleagues and collaborators, current
LabCentral residents and alumni, emerging startups, and other
stakeholders to stimulate conversations on local collaborations and
networking within the Boston/Cambridge biomedical ecosystem.
“We are excited to see how both of these companies will leverage
their Golden Tickets to expand their LabCentral footprint to
advance their programs,” added LabCentral Cofounder and President
Johannes Fruehauf, M.D., Ph.D. “This award is just one example of
how Pfizer is helping to advance great science and support our
growing biotech ecosystem.”
As a LabCentral platinum sponsor, Pfizer can select up to two
qualifying startup companies each year to take up residence in
LabCentral’s Kendall Square facility through use of the Golden
Tickets. Pfizer’s Golden Ticket Program assists high-potential and
innovative early-stage life science and biotech companies. “This
year, we evaluated many eligible U.S. companies,” commented Eileen
Elliott, Pfizer’s Kendall Square Site Lead and Head, Site Affairs
and External Partnership. “Neutrolis and Mediar Therapeutics rose
to the top of the field for their innovative approaches and clear
research visions.”
Neutrolis’ lead candidate, NTR-441, is a first-in-class
therapeutic slated to enter the clinic in early 2021 for lupus and
other serious autoimmune diseases, while Mediar Therapeutics is
focused on the discovery and development of novel, first-in-class
anti-fibrotic therapies for patients.
"We are thrilled to be receiving a Golden Ticket from Pfizer, a
resource that will help foster our research progression," said
Meredith Fisher, Interim Chief Executive Officer of Mediar
Therapeutics. "Having this support so early in our journey is
remarkable and will be a key enabler to our mission.”
“We are appreciative of the Golden Ticket, and we look forward
to using the resources the ticket provides as we advance NTR-441
into the clinic,” added Abdul Hakkim R., PhD., Co-founder and CEO
of Neutrolis.
This is Pfizer’s second year awarding LabCentral Golden Tickets.
Mediar Therapeutics and Neutrolis join Tevard Biosciences and
QurAlis, who were awarded the Company’s 2018 Golden Tickets.
Golden Ticket winners and their use and receipt of a Golden
Ticket are subject to all terms and conditions of the Golden Ticket
Program. A listing of winners (including city of residence, date of
receipt of the prize, and approximate value of the Golden Ticket)
can be obtained by sending a self-addressed stamped envelope to the
following address on or after November 15, 2019: Pfizer Inc.,
Attention: Site Affairs, 1 Portland St., Cambridge, MA 02139.
About Pfizer: Breakthroughs That Change Patients’
Lives
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products, including innovative medicines and vaccines. Every day,
Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our
responsibility as one of the world's premier innovative
biopharmaceutical companies, we collaborate with health care
providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For
more than 150 years, we have worked to make a difference for all
who rely on us. We routinely post information that may be important
to investors on our website at www.Pfizer.com. In addition, to
learn more, please visit us on www.Pfizer.com and follow us on
Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us
on Facebook at Facebook.com/Pfizer.
About LabCentral (www.labcentral.org; twitter
@labcentral)
A private, non-profit institution, LabCentral was founded in
2013 as a launchpad for high-potential life sciences and biotech
start-ups. Operating a total of 100,000 square-feet in the heart of
Kendall Square in Cambridge, Mass., LabCentral offers fully
permitted laboratory and office space for as many as 70 start-ups
comprising approximately 500 scientists and entrepreneurs. More
information is available at www.labcentral.org.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190927005073/en/
Media Relations:
Steve Danehy +1 (212) 733-1538 steven.danehy@Pfizer.com
Investor Relations:
Ryan Crowe +1 (212) 733-8160
Ryan.Crowe@Pfizer.com
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024